Company news

Agios Pharmaceuticals, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Agios Unveils 2023-2026 Value-driving Catalysts Enabling Company’s Vision to Transform Patient Outcomes in Rare Diseases

January 7, 2023

Agios Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Commercial Officer

January 2, 2023

Agios to Present at 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023

December 20, 2022

Agios Presents Updated PYRUKYND® (mitapivat) Long-term Extension Data Demonstrating Sustained Clinical Benefits in Adults with Pyruvate Kinase (PK) Deficiency at 64th ASH Annual Meeting and Exposition

December 10, 2022

Agios Presents Updated PYRUKYND® (mitapivat) Data Highlighting Long-term Safety Profile and Durable Improvement in Hemoglobin and Markers of Hemolysis and Ineffective Erythropoiesis in Non-transfusion-dependent α- and β-Thalassemia at 64th ASH Annual...

December 9, 2022

Agios Appoints Tsveta Milanova as Chief Commercial Officer

December 5, 2022

Agios to Participate in December Investor Conference

November 29, 2022

PYRUKYND® (mitapivat) Approved in the EU for the Treatment of Pyruvate Kinase (PK) Deficiency in Adult Patients

November 9, 2022

Agios Reports Business Highlights and Third Quarter 2022 Financial Results

November 2, 2022

Agios Pharmaceuticals to Present Broad Set of Clinical and Translational Data in Chronic Hemolytic Anemias at 64th ASH Annual Meeting and Exposition

November 2, 2022

Agios and Sagard Healthcare Partners Announce $131.8 Million Purchase Agreement for TIBSOVO® Royalty

October 26, 2022

Agios to Webcast Conference Call of Third Quarter 2022 Financial Results on November 3, 2022

October 19, 2022

Agios Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Financial Officer

September 25, 2022

Agios Appoints Cecilia Jones as Chief Financial Officer

September 18, 2022

Agios Receives Positive CHMP Opinion for PYRUKYND® (mitapivat) for the Treatment of Pyruvate Kinase (PK) Deficiency in Adult Patients

September 15, 2022

Agios to Participate in September Investor Conferences

August 23, 2022

Agios Announces Publication of Phase 3 ACTIVATE-T Data in The Lancet Haematology Demonstrating Benefits of PYRUKYND® (mitapivat) for Adults with Pyruvate Kinase Deficiency

August 17, 2022

Agios Appoints Rahul Ballal and Cynthia Smith to Board of Directors

August 14, 2022

Agios Announces Publication of Phase 2 Data in The Lancet Demonstrating Safety and Efficacy of PYRUKYND® (mitapivat) in Non-transfusion-dependent α- and β-Thalassemia

August 10, 2022

Agios Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Executive Officer

August 7, 2022

Agios Reports Business Highlights and Second Quarter 2022 Financial Results

August 3, 2022

Agios to Webcast Conference Call of Second Quarter 2022 Financial Results on August 4, 2022

July 13, 2022

Agios Appoints Brian Goff as Chief Executive Officer

July 11, 2022

CENTOGENE and Agios Expand Partnership for Clinical Development of PYRUKYND® (mitapivat) to Treat Children With Rare Blood Disease

June 12, 2022

Agios Presents New Clinical Data Supporting the Benefits of PYRUKYND® (mitapivat) Treatment in Adults with PK Deficiency at European Hematology Association Annual Congress

June 9, 2022

Agios Announces Evolution of Research Organization

May 15, 2022

Agios to Present Clinical and Translational Data at the European Hematology Association Annual Congress

May 11, 2022

Agios to Present at the RBC Capital Markets Global Healthcare Conference on May 17, 2022

May 9, 2022

Agios Reports Business Highlights and First Quarter 2022 Financial Results

May 4, 2022

Agios to Webcast Conference Call of First Quarter 2022 Financial Results on May 5, 2022

April 20, 2022

Agios Announces Publication of Phase 3 ACTIVATE Study in New England Journal of Medicine Demonstrating Benefits of PYRUKYND® (mitapivat) for Adults with Pyruvate Kinase Deficiency

April 13, 2022

Agios Reports Fourth Quarter and Full Year 2021 Financial Results

February 23, 2022

Agios Announces FDA Approval of PYRUKYND® (mitapivat) as First Disease-Modifying Therapy for Hemolytic Anemia in Adults with Pyruvate Kinase Deficiency

February 16, 2022

Agios to Webcast Conference Call of Fourth Quarter and Year End 2021 Financial Results on Feb. 24, 2022

February 9, 2022

Agios Highlights 2022 Anticipated Milestones and Priorities to Drive Company’s Strategic Vision in Genetically Defined Diseases

January 9, 2022

Agios to Present at 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022

December 21, 2021

Agios Presents Mitapivat Long-term Extension Data Demonstrating Durability of Hemoglobin Response and Transfusion Burden Reduction in Adults with Pyruvate Kinase (PK) Deficiency at 63rd ASH Annual Meeting and Exposition

December 12, 2021

Agios Presents Mitapivat Data Highlighting Long-term Safety Profile and Durable Improvement in Hemoglobin and Markers of Hemolysis in Non-transfusion-dependent α- and β-Thalassemia at 63rd ASH Annual Meeting and Exposition

December 12, 2021

Agios Announces Data from Investigator-led Studies of Mitapivat in Adults with Sickle Cell Disease Demonstrating Improvements in Anemia, Hemolysis and Sickling Parameters at 63rd ASH Annual Meeting and Exposition

December 12, 2021

Agios Appoints Richa Poddar as Chief Commercial Officer

November 14, 2021

Agios to Present Broad Set of Clinical and Translational Data in Chronic Hemolytic Anemias at 63rd ASH Annual Meeting and Exposition

November 3, 2021

Agios Reports Business Highlights and Third Quarter 2021 Financial Results

November 2, 2021

Agios to Webcast Conference Call of Third Quarter 2021 Financial Results on Nov. 3, 2021

October 20, 2021

Agios To Present at September Investor Conferences

August 29, 2021

Agios Announces FDA Acceptance and Priority Review of New Drug Application for Mitapivat for Treatment of Adults with Pyruvate Kinase Deficiency

August 16, 2021

Agios Reports Business Highlights and Second Quarter 2021 Financial Results

July 28, 2021

Agios to Webcast Conference Call of Second Quarter 2021 Financial Results on July 29, 2021

July 14, 2021

Agios Submits Marketing Authorisation Application to European Medicines Agency for Mitapivat for Treatment of Adults with Pyruvate Kinase Deficiency

June 27, 2021

Agios Launches myAgios® Patient Support Services for Pyruvate Kinase Deficiency

June 21, 2021

Agios Submits New Drug Application to FDA for Mitapivat for Treatment of Adults with Pyruvate Kinase Deficiency

June 20, 2021

← Newer news releases · Older news releases →

Calls

The 5 newest of 26 calls. Every call is listed under its year.

Decks

The 5 newest of 37 decks. Every deck is listed under its year.